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A link between antiretrovirals and perinatal outcomes?
Because starting combination antiretroviral therapy 
(ART) as early as possible is now the norm, all women 
with HIV should be on treatment before becoming 
pregnant (although some women might not be 
diagnosed until they are pregnant). The beneﬁ ts of 
ART are overwhelming, but the risks include adverse 
pregnancy outcomes, which encompass a wide range 
of birth defects and maternal, obstetric, and perinatal 
complications.
A systematic review and meta-analysis1 by Olalekan 
A Uthman and colleagues in The Lancet HIV shows a 
signiﬁ cant increase in preterm births associated with 
ART started before conception compared with ART 
started after conception. Many, though not all, studies 
have shown a strong association between ART and 
preterm births.2 This review is the ﬁ rst in which adverse 
pregnancy outcomes by timing of ART are speciﬁ cally 
assessed. The risk ratios are quite coherent among 
studies from low-income and high-income countries, 
although background risks diﬀ er. The increased risk 
concerns not only moderate preterm birth (ie, delivery 
between 34 and 37 weeks’ gestation) but also deliveries 
at less than 34 weeks’ gestation, which can lead to death 
or permanent disabilities.
The relation between timing of ART initiation and 
other outcomes is less clear. Low birthweight was 
signiﬁ cantly more frequent when ART was started before 
pregnancy than after pregnancy, but the frequency of 
small for gestational age did not diﬀ er signiﬁ cantly 
between groups. Low birthweight can be a proxy for 
preterm birth. By contrast, small for gestational age is, 
by deﬁ nition, adjusted for gestational age. It is also an 
important indication for preterm induction or caesarean 
section. In the French Perinatal Cohort,3 ART was mostly 
associated with induced preterm birth for complications. 
Uthman and colleagues report that the incidence of pre-
eclampsia was independently associated with starting 
ART before conception (rather than after conception). 
Small for gestational age and pre-eclampsia are both 
related to placental dysfunction, which is a consequence 
of faulty trophoblast invasion in early pregnancy. 
However, other studies showed no association between 
ART and pre-eclampsia.4 
There was a non-signiﬁ cant risk of stillbirth, 
which is less frequent than preterm birth and small 
for gestational age, when ART was started before 
conception compared with after conception. The risk of 
congenital anomalies is a major outcome. Congenital 
anomalies were an outcome in only one study5 
included in Uthman and colleagues’ analysis because 
preconception initiation of ART was not distinguished 
from initiation after conception in other studies. The 
teratogenic potential of efavirenz in ﬁ rst-trimester 
ART exposures is controversial.6 In the French Perinatal 
Cohort,7 CNS malformations were increased after ﬁ rst-
trimester exposure to efavirenz, but that study was 
not included in the systematic review because the 
publication did not specify that all these exposures had 
begun before conception (unpublished).
The association between ART and preterm birth 
is intriguing and elusive. Multicentre observational 
cohorts are a good way to study outcomes in large 
populations, but are not designed to inform whether 
starting ART before pregnancy has an eﬀ ect on 
outcomes. An important treatment bias to remember 
is that, until recently, ART used to be reserved for 
people with advanced immune deﬁ ciency. The timing 
of initiation of ART could be important for interactions 
between HIV and the immune system. HIV infection 
is a state of chronic inﬂ ammation. The eﬀ ect of ART 
on this inﬂ ammatory state is complex: it depends on 
immune deﬁ ciency and the viral reservoir at the time 
of treatment initiation. Inﬂ ammation is also a major 
factor in preterm birth, intrauterine growth restriction, 
and pre-eclampsia. Concentrations of inﬂ ammatory 
markers related to microbial translocation were higher 
in pregnant women with HIV than in HIV-negative 
pregnant women,8 and were associated with preterm 
delivery. 
One might thus assume that treating HIV infection 
improves pregnancy outcomes, but the opposite has 
been described.9 The eﬀ ects could diﬀ er regarding 
spontaneous and induced prematurity, with HIV 
infection increasing the frequency of spontaneous 
preterm birth and boosted protease-inhibitor-based 
ART possibly increasing the frequency of induced 
preterm birth.10 Other researchers suggest that ART 
favours spontaneous preterm birth and adverse 
outcomes via the T helper cell 1 and T helper cell 2 
shift or via decreased progesterone concentrations.11 
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Whether the adverse eﬀ ects of ART on pregnancy will 
be increased or decreased by starting treatment earlier 
in the course of HIV infection—ie, before immune 
dysregulation occurs—is unknown,
Another cause for caution is the potential for toxicities 
in the developing fetus and the resulting short-term 
and long-term risks, including mitochondrial diseases, 
cardiac dysfunction, genotoxicity, and cancer, which 
were not topics of Uthman and colleagues’ review but 
are of crucial importance when assessing risks related 
to use of ART in pregnancy. The next step in research 
should be to analyse outcomes according to the 
individual antiretrovirals used and the causes of adverse 
perinatal outcomes. 
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